Lataa...
All in the Levels—Programmed Death‐Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer
Immune checkpoint inhibitors (ICIs) benefit patients with rare subsets of gastrointestinal (GI) cancer. Significant interest exists to identify predictive biomarkers that may increase the applicability of ICI therapy for these patients. Programmed death ligand 1 (PD‐L1) is one such candidate; howeve...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7794187/ https://ncbi.nlm.nih.gov/pubmed/32945067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13526 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|